Background
Survivors of critical illnesses, including COVID-19, are at risk of developing Chronic ICU-Related Pain (CIRP) and neuropathic pain (NP). This study evaluates the incidence of CIRP and NP 6 months after hospital discharge and their impact on pain intensity, functional status, and quality of life (QoL).
Methods
We performed an observational prospective cohort analysis based on a secondary analysis of data from the existing PAIN-COVID randomized controlled trial, which included adult survivors of severe COVID-19 admitted to the ICU. CIRP and NP were assessed at 6 months post-discharge using validated scales (Brief Pain Inventory [BPI] and DN4-interview). Propensity score matching was used to control for confounding factors when comparing pain intensity, functional impact, and QoL between groups.
Results
New-onset CIRP was reported by 47.7% of patients. In matched cohorts, patients with CIRP had significantly lower EQ-5D-5L index (0.705 [0.613–0.818]; p < 0.001) and VAS (72 [60–80]; p = 0.019) scores compared to those without pain. NP affected 36.5% of patients. Patients with NP showed higher BPI-intensity (5.3 [2.5–6], p=0.002) and BPI-interference scores (4.5 [1.5–6.9], p=0.025). The EQ-5D-5L index (0.68 [0.36–0.81]; p = 0.29) and VAS scores (60 [47.5–85]; p = 0.032) were lower compared to those without NP.
Conclusion
A substantial proportion of COVID-19 ICU survivors develop new-onset CIRP and NP within 6 months after discharge, resulting in significant impairment in QoL.
Trial registration
# NCT04394169, registered on 5/19/2020.
扫码关注我们
求助内容:
应助结果提醒方式:
